Aiosyn has live histology endpoints including atherosclerosis, kidney, brain, and liver built with TNO, with more organs coming.

Public source

Publisher name

Public post

🎉 Our new Aiosyn website is live. We're building a multi-organ suite for the histology endpoints in preclinical studies. Our algorithms quantify the entire tissue secti…

Log in to read the full post

Company

Aiosyn

Achieve more perspective through precision pathology

Industry
Medical Equipment Manufacturing
Location
Nijmegen, NL
Company size
2–10 employees

About Aiosyn

Aiosyn is a Dutch healthtech company delivering AI-powered precision pathology solutions to enhance diagnosis and accelerate research in breast cancer and chronic kidney disease. Our algorithms integrate with existing digital pathology software and can be deployed via cloud-based or on-premise installations, ensuring adaptability to diverse laboratory environments. We support digital pathology labs with automated slide quality control (QC) and offer the first IVDR-certified AI solution for mitotic figure counting, improving consistency and efficiency in breast cancer grading. Our NephroPath platform enables quantitative kidney biomarker analysis for CROs and biopharma, helping streamline and scale (pre-)clinical drug development.

See more

Latest activity

6 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.